c-Met/HGFR

c-Met, also called tyrosine-protein kinase Met or hepatocyte growth factor receptor (HGFR), is a protein that in humans is encoded by the MET gene. The protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor.MET is a single pass tyrosine kinase receptor essential for embryonic development, organogenesis and wound healing.

Cat. No.	Product name	CAS No.	Purity
T6117	Tivantinib	905854-02-6	99.95%
T6117	Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.
T7900	BAY-474	1033767-86-0	99.89%
T7900	BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probe
T2894	Norcantharidin	5442-12-6	99.86%
T2894	Norcantharidin (Norcantharadine) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
T8825	Capmatinib 2HCl.H2O	1865733-40-9	99.84%
T8825	Capmatinib 2HCl.H2O (NVP-INC280 2HCl.H2O) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
T25492	Hepln-13	64369-13-7	99.83%
T25492	Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.
T5349	SCR-1481B1	1174161-86-4	99.83%
T5349	SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor
T3209	AMG-337	1173699-31-4	99.82%
T3209	AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337(AMG337) inhibits MET kinase activity (IC50: < 5 nM...
T2419	BMS-794833	1174046-72-0	99.79%
T2419	BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.
TQ0041	Ningetinib Tosylate	1394820-77-9	99.77%
TQ0041	Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
TQ0021	Ningetinib	1394820-69-9	99.77%
TQ0021	Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.
T1963	Capmatinib	1029712-80-8	99.76%
T1963	Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
T13194	CSF1R-IN-2	2271119-26-5	99.71%
T13194	CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).
T8326	BMS-2	888719-03-7	99.7%
T8326	BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
T3113	Foretinib	849217-64-7	99.7%
T3113	Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
T8399	Crizotinib hydrochloride	1415560-69-8	99.67%
T8399	Crizotinib hydrochloride (PF-02341066 hydrochloride) is a novel inhibitor of anaplastic lymphoma kinase and c-Met(IC50s of 20 and 8 nM)
T2293	SGX-523	1022150-57-7	99.6%
T2293	SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
T2586	Cabozantinib	849217-68-1	99.59%
T2586	Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Caboz...
T3455	Merestinib	1206799-15-6	99.56%
T3455	Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity. Merestinib...
T10655	C-Met inhibitor 1	1357072-61-7	99.56%
T10655	c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
T6094	MK-2461	917879-39-1	99.53%
T6094	MK-2461 is a novel inhibitor that targets multiple proteins and competitively binds to ATP sites, specifically inhibiting the activated c-Met protein with an ave...